Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
AIDS and Behavior
Published in: AIDS and Behavior 3/2018

01-03-2018 | Brief Report

Complementary and Alternative Medicine Among Persons living with HIV in the Era of Combined Antiretroviral Treatment

Authors: Sean N. Halpin, Edwin Clayton Carruth, Ramona P. Rai, E. Jennifer Edelman, David A. Fiellin, Cynthia Gibert, Kirsha S. Gordon, Wei Huang, Amy Justice, Vincent C. Marconi, David Rimland, Molly M. Perkins

Published in: AIDS and Behavior | Issue 3/2018

Login to get access

Abstract

Complementary and alternative medicine (CAM), often pursued independent of prescribing clinicians, may interact with traditional treatments, yet CAM use has not been well characterized among people living with HIV (PLWH) in the combined antiretroviral therapy (ART) era. We analyzed data from the Veterans Aging Cohort Study (October 2012–April 2015) to characterize CAM use in PLWH on ART. CAM users were more likely to have lived longer with HIV, report more bothersome symptoms, be prescribed more benzodiazepines and opioids, and consume less nicotine and alcohol. Given its high prevalence, clinicians should routinely assess for CAM use and its impact among PLWH.
Appendix
Available only for authorised users
Literature
1.
Lorenc A, Robinson N. A review of the use of complementary and alternative medicine and HIV: issues for patient care. AIDS Patient Care STDs. 2013;27(9):503–10.CrossRefPubMedPubMedCentral
2.
Astin JA. Why patients use alternative medicine: results of a national study. JAMA. 1998;279(19):1548–53.CrossRefPubMed
3.
Rosenkranz B, Fasinu P, Bouic P. An overview of the evidence and mechanisms of herb–drug interactions. Front Pharmacol. 2012;30(3):69.
4.
Halpin SN, Huang W, Perkins MM. Physicians’ influence on veterans’ decision to use acupuncture. Patient Educ Couns. 2014;97(2):211–5.CrossRefPubMed
5.
Justice AC, Dombrowski E, Conigliaro J, Fultz SL, Gibson D, Madenwald T, Goulet J, Simberkoff M, Butt AA, Rimland D, Rodriguez-Barradas MC. Veterans aging cohort study (VACS): overview and description. Med Care. 2006;44(8 Suppl 2):S13.CrossRefPubMedPubMedCentral
6.
Justice AC, Holmes W, Gifford AL, Rabeneck L, Zackin R, Sinclair G, Weissman S, Neidig J, Marcus C, Chesney M, Cohn SE. Development and validation of a self-completed HIV symptom index. J Clin Epidemiol. 2001;54(12):S77–90.CrossRefPubMed
7.
Weisberg DF, Gordon KS, Barry DT, Becker WC, Crystal S, Edelman EJ, Gaither J, Gordon AJ, Goulet J, Kerns RD, Moore BA. Long-term prescription of opioids and/or benzodiazepines and mortality among HIV-infected and uninfected patients (1999). J Acquir Immun Defic Syndr. 2015;69(2):223–33.CrossRef
8.
Bush K, Kivlahan DR, McDonell MB, Fihn SD, Bradley KA. The AUDIT alcohol consumption questions (AUDIT-C): an effective brief screening test for problem drinking. Arch Intern Med. 1998;158(16):1789–95.CrossRefPubMed
9.
10.
Silverberg MJ, Gore ME, French AL, Gandhi M, Glesby MJ, Kovacs A, Wilson TE, Young MA, Gange SJ. Prevalence of clinical symptoms associated with highly active antiretroviral therapy in the Women’s Interagency HIV Study. Clin Infect Dis. 2004;39(5):717–24.CrossRefPubMedPubMedCentral
11.
Halpin SN, Huang W, Perkins MM. Comparisons between body needle acupuncture, auricular acupuncture, and auricular magnet therapy given to veterans suffering from chronic pain. Am Acupunct. 2015;1:71.
12.
Metadata
Title
Complementary and Alternative Medicine Among Persons living with HIV in the Era of Combined Antiretroviral Treatment
Authors
Sean N. Halpin
Edwin Clayton Carruth
Ramona P. Rai
E. Jennifer Edelman
David A. Fiellin
Cynthia Gibert
Kirsha S. Gordon
Wei Huang
Amy Justice
Vincent C. Marconi
David Rimland
Molly M. Perkins
Publication date
01-03-2018
Publisher
Springer US
Published in
AIDS and Behavior / Issue 3/2018
Print ISSN: 1090-7165
Electronic ISSN: 1573-3254
DOI
https://doi.org/10.1007/s10461-017-1866-7

Other articles of this Issue 3/2018

AIDS and Behavior 3/2018 Go to the issue

Original Paper

How Presentation of Drug Detection Results Changed Reports of Product Adherence in South Africa, Uganda and Zimbabwe

Original Paper

Stumbling Blocks at the Clinic: Experiences of Seeking HIV Treatment and Care in South Africa

OriginalPaper

The Role of Emotional Avoidance, the Patient–Provider Relationship, and Other Social Support in ART Adherence for HIV+ Individuals

Original Paper

Suicidal Ideation Persists Among Individuals Engaged in HIV Care in the Era of Antiretroviral Therapy

OriginalPaper

Correlation of Adherence by Pill Count, Self-report, MEMS and Plasma Drug Levels to Treatment Response Among Women Receiving ARV Therapy for PMTCT in Kenya

Original Paper

Beliefs in Antiretroviral Treatment and Self-Efficacy in HIV Management are Associated with Distinctive HIV Treatment Trajectories
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits